Pipeline

Bacteria: Streptococcus pneumoniae

Serotype: Multivalent

0%

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Bacteria: Klebsiella pneumoniae

Serotype: Bivalent K1/K2

0%

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Bacteria: Group B Streptococcus

Serotype: Multivalent

0%

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Our Vaccines
colorArtboard 2AFC-COLOR
Pneumococcal bioconjugate

Streptococcus pneumoniae, also known as pneumococcus, is one of the most common causes of bacterial acquired pneumonia throughout the world. VaxNewMo is utilizing SBIR/STTR grant awards for advanced development of its multivalent pneumococcal conjugate vaccine, which is continuing preclinical development.

colorArtboard 2AFC-COLOR
Klebsiella pneumoniae bioconjugate

Klebsiella pneumoniae is rapidly emerging as one of the most drug resistant bacteria globally. Commonly the cause of hospital-acquired infections, Klebsiella pneumoniae can also be the cause of deadly community acquired outbreaks due to a hypervirulent pathotype. VaxNewMo is currently developing a bivalent K1/K2 K. pneumoniae bioconjugate to combat both nosocomial and hypervirulent forms of K. pneumoniae again funded through SBIR/STTR grant awards.

colorArtboard 2AFC-COLOR
Group B Streptococcus bioconjugate

Streptococcus agalactiae, more commonly known as Group B Strep (GBS), causes severe neonatal disease and is a leading cause of both stillbirth and preterm birth worldwide. VaxNewMo has recently been funded to develop a multivalent GBS bioconjugate vaccine. While this vaccine is in the discovery stage of development, VaxNewMo leverages existing knowledge gained from other vaccines in our pipeline to accelerate the development of our multivalent GBS bioconjugate vaccine.

colorArtboard 4AFC-COLOR
Contact Us